Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin.
J Cyst Fibros
; 14(5): 594-9, 2015 Sep.
Article
en En
| MEDLINE
| ID: mdl-25735458
ABSTRACT
BACKGROUND:
Azithromycin reduces exacerbations in cystic fibrosis (CF) patients. Our aim was to investigate its association with nontuberculous mycobacteria isolation and macrolide susceptibility.METHODS:
From 2006 to 2010, all adult CF subjects at Cochin Hospital (Paris, France) harboring at least one positive NTM isolate were identified (Cases). In a nested case-control study, each Case was individually matched for age and gender with up to 4 CF adults with no NTM isolate (Controls). Clinical data at the time of first NTM isolate (index date) in Cases were compared with those of Controls using multivariate conditional regression analysis.RESULTS:
CF subjects with positive NTM isolates (Cases, n=41) were matched to 155 Controls. Among Cases, 48.7% had isolates from Mycobacterium avium complex and 58.5% from Mycobacterium abscessus complex, and 31 Cases fulfilled the 2007 American Thoracic Society criteria for NTM infection (ATS+ Cases). Cases and ATS+ Cases were more likely to have low body mass index and colonization with Aspergillus fumigatus. Azithromycin was associated with a two-fold reduction in NTM isolates. Only one M. avium complex isolate had acquired macrolide resistance.CONCLUSION:
These data suggest that azithromycin is a primary prophylaxis for NTM infection in CF adults.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Azitromicina
/
Fibrosis Quística
/
Micobacterias no Tuberculosas
/
Infecciones por Mycobacterium no Tuberculosas
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
J Cyst Fibros
Año:
2015
Tipo del documento:
Article